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Abstract
Objective. To evaluate the oncologic results only in T3 glottic
and supraglottic cancers regarding supracricoid partial laryn-
gectomy (SCPL) not requiring total laryngectomy and to
assess functional results by self-evaluation by the patient.
Study Design. Case series with medical record review.
Setting. Single tertiary care center.
Subjects and Methods. Thirty-two patients with laryngeal
squamous cell carcinoma, previously untreated, who under-
went SCPL with cricohyoidopexy or cricohyoidoepiglotto-
pexy were reviewed.
Results. At 1, 3, and 5 years, the disease-free survival rates
were 96.9%, 89.4%, and 78.2%; overall survival rates were
96.9%, 93.2%, and 87.3%; local control and locoregional con-
trol rates were 100%, 96.2%, and 96.2%; and distant
metastasis–free survival rates were 100%, 100%, and 88.2%,
respectively. Aspiration pneumonia was the most common
complication observed. The 3 laryngeal functions (speech,
swallowing, and breathing) were spared in 83.9% of patients.
Conclusion. Supracricoid partial laryngectomy for selected
glottic and supraglottic T3 tumors has excellent oncologic
and functional results.
Keywords
laryngeal cancer, supracricoid partial laryngectomy, glottic
cancer, supraglottic cancer, T3
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S
upracricoid partial laryngectomies (SCPLs) were first
used for T1-T2 glottic and glottic-supraglottic can-
cers.1-5 In the past 20 years, SCPLs have been adopted
less in T1-T2 cancers because several studies have reported
good survival and functional results by transoral laser surgery
(TLS) or radiotherapy (RT). Recently, TLS has been sug-
gested for T3 laryngeal cancer as well.6,7 After the publica-
tion of a study by the Department of Veterans Affairs
Laryngeal Cancer Study Group (VA)8 and following the
RTOG91-11 studies,9 total laryngectomy (TL) has been used
less as a primary treatment for advanced laryngeal T3-T4
cancers because these studies showed that chemoradiotherapy
(CRT) had a good laryngeal preservation rate. Nevertheless,
some authors were concerned about the CRT strategy for
advanced laryngeal cancers because of the global decrease in
the survival rate compared with TL, especially in T3 cancers,
and the impairment of function even in the presence of anato-
mical organ preservation.10-13
Therefore, in the large T3 ‘‘family,’’ these tumors may
have different therapeutic solutions—TLS,6,7 RT,14 CRT,8,9
and TL—and SCPLs may deserve their own role within
them. Functional results of SCPLs are well documented in
the literature both as primary15-17 and salvage treatment,18-
21 but few data have been reported on the oncologic results
in T3 cancer after SCPLs.3,22-25
The oncologic value of this procedure has been assessed
by grouping different stages of the tumor. Conversely, it
would be important to consider the outcome for patients
with equivalent tumors using different treatment modalities.
Radiotherapy associated or not with chemotherapy for organ
preservation in a candidate for TL is preferably with cate-
gory 1, in accordance with the recommendation cited in the
National Comprehensive Cancer Network (NCCN) guide-
lines,26 while the same option in a resectable tumor through
conservative surgery merits discussion.
The aim of this study was to evaluate the oncologic
results only in T3 glottic and supraglottic cancers regarding
SCPL not requiring TL. The second aim of the study was to
assess functional results by self-evaluation from the patient.
Patients and Methods
We retrospectively reviewed the medical records of consec-
utive patients with laryngeal squamous cell carcinoma,
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previously untreated, cured with SCPL between 2003 and
2012 at the Regina-Elena National Cancer Institute in
Rome, Italy. This study was approved by the National
Cancer Institute Institutional Review Board.
Of 86 patients who underwent SCPL, we selected 32
affected by T3 laryngeal cancer. All cases were discussed
with our disease management team. When alternative treat-
ments were possible, we usually offered different options to
patients who made the choice. The surgical technique was
performed according to the technique originally described in
the literature, using crichohyoidepiglottopexy (CHEP) or
crichohyoidopexy (CHP) while considering tumor location
and extension.1,2,4,5 All patients underwent spirometry for
pulmonary evaluation. Adequate pulmonary reserve was
considered mandatory to tolerate the increased postoperative
aspiration. Patients with severe chronic obstructive pulmon-
ary disease and impairment of the cough reflex were consid-
ered unsuitable for SCPL.
All patients underwent simultaneous monolateral/bilateral
neck dissection, selective (II-IV) or modified radical (II-V),
according to the site of T and the status of N. The demo-
graphic and clinical data of the patients are reported in
Table 1. The disease was reclassified in all patients accord-
ing to the Union for International Cancer Control–TNM
classification.27
Nasogastric feeding tube (NGT) was always placed, and
tracheostomy was always performed. The tracheostomy tube
was removed and the stoma was closed if the patient toler-
ated it well without dyspnea. The NGT was removed after
the patient regained swallow function of both solids and
liquids without aspiration, under speech therapist supervision.
Postoperative RT was indicated for pT4a, a minimum of
2 positive nodes without extracapsular spread (ECS1), or
both. Chemoradiotherapy was indicated for nodal ECS1.
The end points of the study were the relapses on T, N,
and M affecting local control (LC), locoregional control
(LRC), and distant metastasis (DM) rates, respectively, at
years 1, 3, and 5. The survival was calculated as disease-
free survival (DFS) and overall survival (OS) at years 1, 3,
and 5. The complications that occurred after SCPL were
also investigated and divided between intraoperative, early
(30 postoperative days), and late (.30 postoperative days)
complications. For the functional outcome evaluation, the
mean time of decannulation and NGT removal used breath-
ing and swallowing recovery as indicators. Patient-related
factors such as age and sex together with surgical-related
factors (sparing 1 or both the arytenoids) were analyzed in
relation to functional outcome. The early evaluation of
speech was not done. The long-term results were assessed at
least 6 months after surgery, interviewing each patient about
his or her postoperative swallowing and evaluating the
degree of postoperative aspiration according to the
Leipzig28 and Pearson29 scales (1 = none, 2 = occasional
cough but no clinical problems, 3 = constant cough worsen-
ing with meals or swallowing, 4 = pulmonary complica-
tions). The same criteria with the Leipzig28 and Pearson29
scales were adopted to evaluate speech (1 = excellent
subjective speech, 2 = communication with voice primarily,
3 = occasional word or syllable produced, 4 = requires lip
reading to understand sounds).
The variables were tested by the Pearson x2 test or
Fisher exact test, when appropriate. Significance was
defined at the P  .05 level. All survival curves were calcu-
lated by the Kaplan-Meier product-limit method SPSS soft-
ware (version 20.0; SPSS, Inc, an IBM Company, Chicago,
Illinois) and for all statistical evaluations.
Results
Thirty male (94%) and 2 female (6%) patients with a mean
(SD) age of 62 (12) years (range, 24-80 years) fulfilled the
inclusion criteria of the study. Twenty-four of 32 patients
had glottic and 8 of 32 had glottic-supraglottic neoplasia.
Supracricoid partial laryngectomy was performed with CHP
in 18 (56%) cases and with CHEP in 14 (44%) cases. One
arytenoid was spared in 29 (91%) cases, while both were
spared in 3 (9%) cases. Patients were smokers in 28 (88%)
cases and nonsmokers in 4 (12%) cases. All patients were
clinically staged as T3: 27 (85%) N0, 3 (9%) N1, and 2
(6%) N2b. The final pathology report staged 7 (22%) cases
Table 1. Demographic and clinical data of the patients (n = 33).
Patient Characteristics No. (%)
Sex
Male 30 (94)
Female 2 (6)
Age, y
Range 24-80
Median 64.8
Follow-up, mo
Range 6-116
Median 47.3
T3 tumor subsite
Glottis 24 (75)
Glottis/supraglottis 8 (25)
Pathological nodal stage
N0 26 (82)
N1 3 (9)
N2b 3 (9)
Type of laryngectomy
CHEP 14 (44)
CHP 18 (56)
Type of neck dissection
HSND 17 (54)
BSND 9 (28)
SND 1 MRND 4 (14)
HMRND 1 (4)
Abbreviations: BSND, bilateral selective neck dissection (levels II-IV); CHEP,
crichohyoidepiglottopexy; CHP, crichohyoidopexy; HMRND, homolateral
modified radical neck dissection; HSND, homolateral selective neck dissec-
tion (levels II-IV); SND 1 MRND, selective neck dissection 1 modified rad-
ical neck dissection.
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as T2, 19 (59%) as T3, and 6 (19%) as T4a, as well as 26
(82%) as N0, 3 (9%) as N1, 3 (9%) as N2b. Perinueral inva-
sion was never observed. Surgical margins were always free
of tumor. Postoperative RT was used in 2 (6%) patients
(both pT4aN0), and postoperative CRT was used in 3 (9%)
patients (1 with pT3pN2b and 2 with pT4apN2b, all with
ECS1).
No intraoperative complications were observed. Eight
(25%) patients had early complications (4 surgical and 4
medical). The 4 surgical complications were hematomas on
the first postoperative day, which were treated with a surgi-
cal revision (3 cases), and the pharyngocutaneous fistula (1
case) was treated with dressings. Aspiration pneumonia was
the early medical complication in 4 cases. One patient died
of pneumonia after 23 days of recovery in the intensive care
unit. Medical therapy was successfully administered in the
other 3 cases, even when positioning of percutaneous endo-
scopic gastrostomy (PEG) tubes was required in 2. Three
(9%) patients had late complications (2 cases of neolaryn-
geal stenosis and 1 case of aspiration pneumonia). All were
treated by repositioning of a tracheostomy tube and with
medical therapy (Table 2).
Follow-up after surgery varied from 6 to 116 months,
with a median of 47.3 months.
The DFS rates at 1, 3, and 5 years were 96.9%, 89.4%,
and 78.2%, respectively. The OS rates at 1, 3, and 5 years
were 96.9%, 93.2%, and 87.3%, respectively (Figure 1).
One patient (3%) who developed a local recurrence after
16 months underwent CRT as salvage treatment and died of
the disease. No recurrence on the neck was observed. Two
(6%) patients had lung metastasis after 37 and 41 months.
One of them survives after 20 months of chemotherapy,
while the other died of the disease. Another patient (3%)
was diagnosed for a second primary tumor on the lung.
Twenty-three months after surgery, the patient was treated
with surgery and still survives after 3 years without
evidence of disease. Thus, the LC and the LCR rates at 1, 3,
and 5 years were 100%, 96.2%, and 96.2%, respectively.
The DM-free survival rates at 1, 3, and 5 years were 100%,
100%, and 88.2%, respectively (Figure 2).
Results of swallowing and speech of 31 live patients
were assessed after 6 months of surgery once the postopera-
tive healing process was completed. Decannulation was
achieved in 28 of 31 (91%) patients. The 3 patients who
maintained the tracheostomy tube had an edema of the neo-
larynx and did not tolerate the closure of the stoma. The
mean (SD) decannulation time was 15 (10) days. The NGT
was removed in all patients. Two (6%) patients were not
able to swallow without aspiration and underwent PEG. The
Table 2. Complications after supracricoid partial laryngectomy.
Complications (n) Treatment Results
Medical
Early
Aspiration pneumonia (4) Medical therapy 1 cured
1 patient died on PO day 23
2 patients required PEG positioning
Late
Neolarynx stenosis (2) Repositioning of tracheostomy tube Normalization of breathing
Aspiration pneumonia (1) Medical therapy Complete healing
Surgical
Early
Wound hematoma (3) Surgical revision Complete healing
Pharyngocutaneous fistula (1) Dressings Complete healing
Late
None
Abbreviations: PEG, percutaneous endoscopic gastrostomy; PO, postoperative.
Figure 1. Survival in relation to time. Disease-free survival, dotted
line; overall survival, solid line.
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mean (SD) time of NGT removal was 28 (19) days. The sta-
tistical analysis did not show any difference between decan-
nulation and/or deglutition by age and sex as well as the
type of surgery (SCPL with CHP/CHEP) and the presence
of 1 or both arytenoids.
Among the 31 patients evaluated for subjective aspiration
and for assessment of swallowing by the Leipzig28 and
Pearson29 scales, 21 (68%) were classified as group 1, 4
(13%) as group 2, 5 (16%) as group 3, and 1 (3%) as group
4. Of the 2 patients with PEG, 1 was in group 3 and 1 was
in group 4. Both patients, due to good voice and breathing
(grade 1), had preferred to maintain PEG and refused func-
tional TL. Evaluation of speech with the Leipzig28 and
Pearson29 scales showed grade 1 in 27 (87%) cases and
grade 2 in 4 (13%).
Discussion
A wide consensus shows that oncological and functional
results of glottic and supraglottic T1 (stage I) and T2 (stage
II) tumors treated by TLS or RT are equivalent, reaching
80% to 95% of disease LC.17,30-34 The VA and RTOG91-11
studies8-9,35 evaluated RT and CRT as an alternative to TL
for stage III/IV glottic and supraglottic advanced laryngeal
cancer in terms of laryngeal preservation without survival
detriment. The NCCN guidelines divide T3 laryngeal cancer
into 2 categories regarding treatment options: ‘‘select T3
not requiring TL’’ and ‘‘most T3 requiring TL.’’ The
NCCN guidelines indicate conservative surgery or RT alone
for the ‘‘select T3 not requiring TL’’ group, while CRT is
the best option with a category 1 recommendation for the
‘‘T3 requiring TL’’ group. Consequently, the T3 stage
should be treated in 2 different ways according to whether
TL is necessary. In practice, most institutions opt for CRT
as the preferred nonsurgical option for T3 tumors. The risk
for the patient is considered unsuitable for such a challen-
ging surgical procedure, as SCPL is considered; as a
consequence, CRT could be a unique alternative to TL. A
recent study showed that conservative surgery for T3 laryn-
geal cancer has yet to be considered an option.14 From the
literature, 5-year DFS for advanced laryngeal cancer after
RT or CRT varies between 28% and 58%.14,35 The best
results are obtained in T3, even if only 50% to 80% of the
survivors retain their larynx.8,14,35
Hoffman et al10 reported a decrease in survival for laryn-
geal cancer, when the 1990s were compared with the 1980s,
that can be related to the use of CRT. Olsen13 was con-
cerned about a debatable laryngeal function despite ana-
tomic preservation. Lefebvre and Ang36 stressed the concept
of excluding CRT patients who were candidates for a partial
laryngectomy, excluding patients with pretracheotomy, and
assessing the functional outcome of the preserved larynx.
Careful evaluation of the potential effects on survival as
well as the likelihood of retained function must precede the
use of organ-preserving regimens for advanced-stage laryn-
geal cancer. Just as resection of a structure that can be
cured oncologically and preserved functionally with nonsur-
gical treatment does not seem reasonable, resistance to exci-
sion of resectable tumors that are likely to have poor
residual function after organ-preserving CRT regimens is
similarly problematic. This is especially true in the latter
instance if the nonsurgical approach has the potential to
result in decreased survival or increased morbidity.37
We reviewed the subgroup of patients classified as
‘‘select T3 not requiring TL’’ and submitted to SCPL,
which represented 37% of all SCPLs performed in the same
period and 23% of all T3 observed in the same period (32/
139); all others were treated by TL, RT, or CRT. In this
study, there were biases related to the selection of patients
and tumors, but the decision on therapy, based on perfor-
mance status, is important for candidates for SCPL as well
as for CRT. The performance status score of candidates for
SCPL or CRT is expected to be similar. For patients with
those characteristics (cT3 amenable to SCPL) and without
patient-related contraindications, the policy of the tumor
board of our institution was to offer the patient a choice
between SCPL and nonsurgical options. Thus, the bias pres-
ent regarded patient preference.
We observed a 5-year DFS and OS of 78.2% and 87.3%,
respectively. The LC and LCR at 5 years were 96.6%. This
is the real value of the procedure, which is considered
excellent. The decrease in OS was due to distant metastasis
and second primary cancer. The high survival rate of glottic
and supraglottic T3 laryngeal cancer confirms previously
published papers.3,22,23 All patients maintained their larynx.
Literature data may be influenced by the use of postopera-
tive RT as reported by Lima et al.22 In their study, 62.5% of
patients underwent adjuvant RT or CRT, and thus the real
efficacy of the surgery can be hidden by adjuvant treatment.
In our study, only 5 of 32 patients benefited from adjuvant
treatment, and therefore the efficacy of surgery alone was
tested in 85% of cases. We achieved 5-year LC, LCR, and
DM-free survival rates of 96.2%, 96.2%, and 88.2%, respec-
tively. Only 1 patient with local recurrence died after
Figure 2. Survival and disease control in relation to time. DFS, dis-
ease free survival; OS, overall survival; LC, local control; LCR, local
control rate; DMFS, distant metastasis–free survival.
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refusing TL. The high rate of LC represents the greatest
advantage of this technique compared with TLS. According
to Blanch et al,38 TLS is feasible in selected T3 laryngeal
cancers with disease-specific survival and laryngectomy-
free survival of 79.5% and 71.4% but with a local recur-
rence rate of 38%. Furthermore, in general, the selection of
these T3 tumors suitable for endoscopic removal should be
carried out with much caution.6,7 In contrast, SCPL has
fewer limitations than TLS because it allows ‘‘en bloc’’
removal of the entire thyroid cartilage and its surrounding
soft tissue structures, with wide surgical margins.
The nonsurgical alternative for these patients would be
RT or CRT. The retrospective comparison is not feasible
due to the bias in the selection of both approaches. In any
case, such high rates of LC and OS are not reported in non-
surgical treatment series for T3.8,9,14
Several controversies exist regarding neck dissection
(ND) associated with SCPL due to the low rate of neck
metastasis.24 In the present study, all patients underwent an
ND, even in N0 cases, due to the risk of occult nodal metas-
tasis in T3. The evidence of pathologic nodes was 18%. We
have had no regional failure or complications related to ND.
The adopted policy (SCPL 1 ND) allowed us to have a
final pathology report showing an over (19%) or under
(22%) stage on T, documenting the exact number of lymph
nodes affected and the presence of ECS1. As a result, it
was possible to tailor the best adjuvant treatment for each
patient.
Some authors have already demonstrated the acceptable
functional results of the procedure.15,39,40 Good functional
results translate into recovery of the 3 main functions of the
larynx: voice, breathing, and swallowing. Our patients
achieved good swallowing and speech ability as expected
by the literature, even if early or late complications occurred
in 34%. Speech was subjectively judged as satisfying. Other
authors have demonstrated that speech is obviously worse
compared with normal subjects.16 Twenty-eight of 31 cases
were decannulated, and 3 still use a tracheostomy. Of the
patients, 81% were able to swallow without any risk of
developing pneumonia. Twelve percent had early surgical
complications that were easily managed, while 15% had
aspiration pneumonia that required medical therapy alone (1
case), medical therapy and repositioning of the tracheost-
omy tube (1 case), or medical therapy and positioning of
PEG (2 cases). One patient was admitted at the intensive
care unit for respiratory failure and died despite therapy.
The mortality rate related to surgery was 3% (1/32).
Forastiere et al9 reported an incidence of grade 3 or 4 late
toxic effects of 24% to 36% in the RTOG91-11 study. In
our study, 2 of 32 cases had an unexpected high incidence
of severe dysphagia and still require PEG feeding, compared
with 2 of 78 cases of salvage SCPL after RT failure docu-
mented in a previous study.20 Permanent tracheostomy in
9% may seem a high incidence rate compared with similar
reported cases, but the presence of a tracheostomy is also
reported in nonsurgical studies.8,9
The voice quality score was very good in our series
according to the patients’ judgment. However, worse voice
scores resulted compared with nonsurgical reports.
In all the nonsurgical series using RT or CRT, the end
point was survival and larynx preservation. Thus, the live
patients were divided into 2 groups (with or without a
larynx). All live patients in our series had a preserved
larynx. However, 26 of 31 had all 3 functions restored, 29
of 31 had both breathing and voice preservation, and 28 of
31 had at least swallowing and voice restoration. The differ-
ent functional results in similar studies may also be related
to the type of SCPL. Lima et al22 reported one of the largest
published series with 107 CHEPs of 110 SCPLs. In contrast,
the number of CHPs and CHEPs was similar in our series,
with 91% of patients having only 1 arytenoid preserved and
all patients having ND. Therefore, different functional
results must be related to these technical variables.
For T3 cancer, a comparison of functional results regard-
ing SCPL in this study and RT or CRT in the literature is
not feasible. Nevertheless, we should expect considerably
more early complications than late ones with SCPL com-
pared with RT and CRT and vice versa. In the present
study, all surviving patients retained their larynx with a high
LC rate. Data from published studies obviously cannot be
compared, and a randomized prospective study comparing
oncologic and functional outcomes of SCPL and RT or
CRT in T3 cancer should be performed, despite the diffi-
culty in obtaining a consensus from patients to be rando-
mized in a surgical or nonsurgical arm.
Conclusions
Supracricoid partial laryngectomy for selected glottic and
supraglottic T3 tumors has excellent oncologic and func-
tional results. By far, the most common complication is
aspiration pneumonia. Selection of patients and tumors rep-
resents a pivotal step toward achieving good results. In T3
laryngeal cancer, SCPL is an important treatment option to
be included in the available armamentarium.
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